StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Sign in to jot down a private note about UNCY. Only you ever see it.
External sites have their own terms, paywalls, and accuracy standards. Stonvex doesn't endorse the content there.
Three bull points, three bear points, and one “what would change my mind” line — both sides forced onto one screen as a research note rather than a tip sheet.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2023 2023-12-31 | Q3 2023 2023-09-30 | Q2 2023 2023-06-30 | Q1 2023 2023-03-31 |
|---|---|---|---|---|
Revenue | $675.00K | $675.00K | $675.00K | $675.00K |
Operating Income | $-20.77M | $-14.46M | $-8.52M | $-4.20M |
Net Income | $-30.54M | $-22.75M | $-3.84M | $-14.57M |
EPS (Diluted) | $-1.28 | $-1.12 | $-1.26 | $-0.97 |
Total Assets | $14.19M | $19.44M | $22.88M | $27.20M |
Total Liabilities | $18.00M | $16.01M | $16.05M | $16.68M |
Cash & Equivalents | $9.70M | $14.35M | $18.82M | $24.33M |
Free Cash Flow OCF − CapEx | $-18.30M | $-13.86M | $-9.43M | Not available |
Shares Outstanding | 34.76M | 34.75M | 15.24M | 15.23M |
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.